The First Affiliated Hospital Of Soochow University

This study is testing whether combining two drugs, venetoclax and azacitidine, is safe and effective as an initial treatment for adults with a fast-growing type of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL). The trial will enroll 28 newly diagnosed patients t…

This is a first-in-human study to test the safety and find the right dose of a new oral drug called BY002. It is for adults with acute leukemia that has returned or not responded to standard treatments, particularly those with specific genetic changes. The main goals are to see h…

This study is testing a new combination of three drugs for adults with an aggressive type of blood cancer called peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior treatment. About 26 patients will receive the drug combination for up to 6 cycles, follow…

This study is testing whether adding one of two extra drugs to a standard leukemia treatment works better for older adults or those who cannot tolerate intensive chemotherapy. Researchers want to see if these new combinations can kill leukemia cells more effectively, prevent drug…

This study is testing whether adding a drug called chidamide to an existing two-drug combination (venetoclax and azacytidine) works better for newly diagnosed acute monocytic leukemia patients who are too old or frail for intensive chemotherapy. The trial aims to see if this thre…

This is an early-stage study testing a new type of CAR-T cell therapy called CXCR4 CCR9 CAR-T in patients whose T-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. The main goals are to find a safe dose, check for side effects, and get an early l…

This is an early-phase study testing a new type of personalized immune cell therapy called CT0596 CAR-T. It aims to see if this treatment is safe and effective for adults with multiple myeloma or plasma cell leukemia that has come back or stopped responding to other treatments. T…

This study is testing a combination of three treatments for people whose acute myeloid leukemia (AML) has come back after a stem cell transplant. The goal is to see if the combination can control the disease and is safe for patients. It is for adults aged 18-60 who have relapsed …

This study is testing a combination of existing drugs to treat a dangerous immune system overreaction called HLH in people with B-cell lymphoma. The goal is to control this severe complication and improve survival. About 40 patients will receive the drug combination for 4 weeks, …

This study aims to find the best maintenance therapy to prevent cancer from returning in patients with a specific genetic type of acute myeloid leukemia (AML) who have received a stem cell transplant. Researchers will compare two drugs, gilteritinib and sorafenib, given for two y…

This study is testing whether combining five different medications can help control a rare and aggressive form of adult leukemia called ETP-ALL. Researchers want to see if this combination is safe and effective for newly diagnosed patients who haven't received other treatments. T…

This study is testing a new treatment approach for adults with marginal zone lymphoma (MZL), a slow-growing blood cancer, who haven't had prior systemic therapy. It combines a short course of standard chemotherapy with a longer period of a newer, targeted pill called orelabrutini…

This study is testing a new combination of three drugs (venetoclax, cladribine, and cytarabine) for adults with a specific type of acute lymphoblastic leukemia (ALL) that has returned or not responded to previous treatments. The goal is to see if this drug combo can effectively c…

This study is testing a new treatment combination for adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). The goal is to see if a regimen based on the drug venetoclax, which avoids harsh traditional chemotherapy drugs called anthracyclines, can ef…

This study is testing a new treatment approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a standard donor stem cell transplant. Researchers are combining an immunotherapy drug called blinatumomab with a transplant using the patie…

This is an early-stage study to check the safety and body's response to a new drug called IBI3002 for people with asthma. It will involve a small group of adults whose asthma is not fully controlled despite using standard inhalers. Participants will receive injections of either t…

This study is testing whether a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) can help control acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. It will involve 68 patients aged 16-70 to see if this new comb…

This study is testing whether combining two existing drugs can help adults with a rare blood disorder called immune thrombocytopenia (ITP) when standard oral medications have failed. All 30 participants will receive weekly infusions of one drug and weekly injections of another, w…

This study is testing whether giving a maintenance drug after standard treatment can help keep favorable-risk acute myeloid leukemia (AML) in remission longer and improve survival. It will involve about 77 patients who have already achieved remission with initial therapy and have…

This study is testing whether adding a drug called chidamide to a standard two-drug leukemia treatment can help patients who didn't respond well enough to the standard treatment alone. It is for adults with acute myeloid leukemia (AML) who are older or cannot tolerate strong chem…

This study is testing a three-drug combination (venetoclax pills plus two injectable drugs) to treat adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML) who are too frail for standard intensive chemotherapy. The main goals are to see how well this …

This study is testing which of two drug regimens works better to prepare high-risk or relapsed acute leukemia patients for a stem cell transplant. Researchers will compare a new combination called TmBU against a standard modified Bu/Cy regimen. The main goal is to see which appro…

This study is testing a new combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The goal is to see if …

This study is testing if giving an antiviral drug called letermovir for a longer period (up to 24 weeks) can better prevent dangerous CMV infections in high-risk adults who have received a stem cell transplant from a donor. CMV is a common virus that can cause serious illness in …

This study is testing whether transplanting a patient's own healthy gut bacteria back into them can prevent a dangerous immune reaction called acute graft-versus-host disease (GVHD) after a half-matched bone marrow transplant. Researchers are recruiting 100 patients who have rece…

This study is testing whether the temperature of the numbing medicine used in epidurals affects how often mothers get a fever during labor. Researchers are comparing a warm solution (37°C) to a room-temperature one (23°C) in 424 women receiving epidurals. The goal is to see if wa…

This study is testing whether a non-invasive brain stimulation technique can reduce chronic stomach pain in people with Irritable Bowel Syndrome with diarrhea (IBS-D). Researchers are recruiting 42 adults with IBS-D to receive either real or fake magnetic stimulation to a specifi…

This study aims to understand how nutrition affects recovery for people who have had a stem cell transplant. Researchers will follow 200 patients for six months, tracking their food intake, body composition, and blood markers. The goal is to learn how diet and weight changes rela…

This study aims to understand if there's a link between how a person's gut bacteria break down certain dietary carbohydrates (called FODMAPs) and their risk of developing graft-versus-host disease (GVHD) after a bone marrow transplant. Researchers will recruit 100 patients who ha…